{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T12:56:01Z","timestamp":1769086561080,"version":"3.49.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12029-025-01215-x","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T22:23:25Z","timestamp":1743719005000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Combined Chemotherapy-Immunotherapy for Advanced Biliary Tract Cancer (BTC): A Clinical, Genomic, and Biomarker Analysis"],"prefix":"10.1007","volume":"56","author":[{"given":"Yong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miaomiao","family":"Gou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,1]]},"reference":[{"issue":"9","key":"1215_CR1","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","volume":"17","author":"JM Banales","year":"2020","unstructured":"Banales JM, Marin J, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17(9):557\u201388.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"1215_CR2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71(1):7\u201333.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"1215_CR3","first-page":"221","volume":"46","author":"RS Zheng","year":"2024","unstructured":"Zheng RS, Chen R, Han BF, et al. Cancer incidence and mortality in China, 2022. Zhonghua Zhong Liu Za Zhi. 2024;46(3):221\u201331.","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"issue":"10272","key":"1215_CR4","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","volume":"397","author":"JW Valle","year":"2021","unstructured":"Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary tract cancer. Lancet. 2021;397(10272):428\u201344.","journal-title":"Lancet"},{"issue":"14","key":"1215_CR5","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273\u201381.","journal-title":"N Engl J Med"},{"issue":"2","key":"1215_CR6","doi-asserted-by":"crossref","first-page":"909","DOI":"10.21873\/anticanres.11398","volume":"37","author":"S Arima","year":"2017","unstructured":"Arima S, Shimizu K, Okamoto T, et al. A multicenter phase II study of gemcitabine plus S-1 chemotherapy for advanced biliary tract cancer. Anticancer Res. 2017;37(2):909\u201314.","journal-title":"Anticancer Res"},{"issue":"6","key":"1215_CR7","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/sj.bjc.6604628","volume":"99","author":"T Andr\u00e9","year":"2008","unstructured":"Andr\u00e9 T, Reyes-Vidal JM, Fartoux L, et al. Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study. Br J Cancer. 2008;99(6):862\u20137.","journal-title":"Br J Cancer"},{"key":"1215_CR8","doi-asserted-by":"publisher","unstructured":"Shroff RT, Guthrie KA, Scott AJ, Borad MJ, Goff LW, Matin K et al. SWOG 1815: a phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers. JCO. 2023;41, LBA490. https:\/\/doi.org\/10.1200\/JCO.2023.41.4_suppl.LBA49","DOI":"10.1200\/JCO.2023.41.4_suppl.LBA49"},{"issue":"2","key":"1215_CR9","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/annonc\/mdy540","volume":"30","author":"N Boku","year":"2019","unstructured":"Boku N, Ryu MH, Kato K, Chung HC, Minashi K, Lee KW, Cho H, Kang WK, Komatsu Y, Tsuda M, Yamaguchi K, Hara H, Fumita S, Azuma M, Chen LT, Kang YK. Safety and efficacy of nivolumab in combination with S-1\/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric\/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4). Ann Oncol. 2019;30(2):250\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdy540.","journal-title":"Ann Oncol"},{"key":"1215_CR10","doi-asserted-by":"publisher","unstructured":"Kato K, Sun JM, Shah MA, Enzinger PC, Adenis A, Kojima T et al. LBA8_PR - pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: the phase 3 KEYNOTE-590 study. Ann Oncol. 2020; 31(suppl_4):S1142-S1215. https:\/\/doi.org\/10.1016\/annonc\/annonc325.","DOI":"10.1016\/annonc\/annonc325"},{"issue":"10294","key":"1215_CR11","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27\u201340.","journal-title":"Lancet"},{"issue":"35","key":"1215_CR12","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1200\/JCO.2017.74.3062","volume":"35","author":"L Horn","year":"2017","unstructured":"Horn L, Spigel DR, Vokes EE, et al. Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057). J Clin Oncol. 2017;35(35):3924\u201333.","journal-title":"J Clin Oncol"},{"issue":"13","key":"1215_CR13","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1056\/NEJMc1509660","volume":"373","author":"ME Valsecchi","year":"2015","unstructured":"Valsecchi ME. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(13):1270.","journal-title":"N Engl J Med"},{"issue":"8","key":"1215_CR14","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1002\/ijc.33013","volume":"147","author":"SA Piha-Paul","year":"2020","unstructured":"Piha-Paul SA, Oh DY, Ueno M, et al. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE-158 and KEYNOTE-028 studies. Int J Cancer. 2020;147(8):2190\u20138.","journal-title":"Int J Cancer"},{"key":"1215_CR15","doi-asserted-by":"crossref","unstructured":"Chen X, Wu X, Wu H et al. SHR-1210 plus GEMOX as first line treatment in biliary tract cancer: results from a single-arm exploratory study. J Clin Oncol JCO. 2019; 37(15_suppl):4092\u20134092.","DOI":"10.1200\/JCO.2019.37.15_suppl.4092"},{"issue":"9","key":"1215_CR16","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1007\/s00262-019-02386-w","volume":"68","author":"D Sun","year":"2019","unstructured":"Sun D, Ma J, Wang J, et al. Anti-PD-1 therapy combined with chemotherapy in patients with advanced biliary tract cancer. Cancer Immunol Immunother. 2019;68(9):1527\u201335.","journal-title":"Cancer Immunol Immunother"},{"issue":"8","key":"1215_CR17","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S2468-1253(19)30086-X","volume":"4","author":"M Ueno","year":"2019","unstructured":"Ueno M, Ikeda M, Morizane C, et al. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study. Lancet Gastroenterol Hepatol. 2019;4(8):611\u201321.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"1215_CR18","first-page":"100255","volume":"3","author":"W Li","year":"2022","unstructured":"Li W, Wang Y, Yu Y, et al. Toripalimab in advanced biliary tract cancer. Innovation (Camb). 2022;3(4):100255.","journal-title":"Innovation (Camb)"},{"issue":"5","key":"1215_CR19","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S1470-2045(24)00082-2","volume":"25","author":"HA Burris 3rd","year":"2024","unstructured":"Burris HA 3rd, Okusaka T, Vogel A, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2024;25(5):626\u201335.","journal-title":"Lancet Oncol"},{"issue":"10391","key":"1215_CR20","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401(10391):1853\u201365.","journal-title":"Lancet"},{"key":"1215_CR21","doi-asserted-by":"crossref","unstructured":"Vogel A, Chen L, He AR, Kim JW, Chen M-H, McNamara MG et al. Regional subgroup analysis of the phase 3 TOPAZ-1 study of durvalumab (D) plus gemcitabine and cisplatin (GC) in advanced biliary tract cancer (BTC). J Clin Oncol.2022;40(16_suppl):4075\u20134075.","DOI":"10.1200\/JCO.2022.40.16_suppl.4075"},{"issue":"19","key":"1215_CR22","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1002\/cncr.34394","volume":"128","author":"V Sahai","year":"2022","unstructured":"Sahai V, Griffith KA, Beg MS, et al. A randomized phase 2 trial of nivolumab, gemcitabine, and cisplatin or nivolumab and ipilimumab in previously untreated advanced biliary cancer: BilT-01. Cancer. 2022;128(19):3523\u201330.","journal-title":"Cancer"},{"issue":"1","key":"1215_CR23","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1038\/s41467-023-37030-w","volume":"14","author":"TM Zeng","year":"2023","unstructured":"Zeng TM, Yang G, Lou C, et al. Clinical and biomarker analyses of sintilimab plus gemcitabine and cisplatin as first-line treatment for patients with advanced biliary tract cancer. Nat Commun. 2023;14(1):1340.","journal-title":"Nat Commun"},{"key":"1215_CR24","doi-asserted-by":"publisher","unstructured":"Feng K, Liu Y, Zhao Y et al. Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study. J Immunother Cancer. 2020;8(1). https:\/\/doi.org\/10.1136\/jitc-2019-000367","DOI":"10.1136\/jitc-2019-000367"},{"key":"1215_CR25","doi-asserted-by":"crossref","first-page":"S377","DOI":"10.1016\/j.annonc.2021.08.328","volume":"32","author":"N-J Chiang","year":"2021","unstructured":"Chiang N-J, et al. 49P A phase II trial of nivolumab and gemcitabine and S-1 as the first-line treatment in patients with advanced biliary tract cancer. Ann Oncol. 2021;32:S377.","journal-title":"Ann Oncol."},{"issue":"4","key":"1215_CR26","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/jjco\/hyv213","volume":"46","author":"J Mizusawa","year":"2016","unstructured":"Mizusawa J, Morizane C, Okusaka T, et al. Randomized phase III study of gemcitabine plus S-1 versus gemcitabine plus cisplatin in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1113, FUGA-BT). Jpn J Clin Oncol. 2016;46(4):385\u20138.","journal-title":"Jpn J Clin Oncol"},{"issue":"12","key":"1215_CR27","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1001\/jamaoncol.2018.3277","volume":"4","author":"V Sahai","year":"2018","unstructured":"Sahai V, Catalano PJ, Zalupski MM, et al. Nab-paclitaxel and gemcitabine as first-line treatment of advanced or metastatic cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol. 2018;4(12):1707\u201312.","journal-title":"JAMA Oncol"},{"issue":"2","key":"1215_CR28","doi-asserted-by":"crossref","first-page":"602","DOI":"10.4143\/crt.2023.726","volume":"56","author":"T Liu","year":"2024","unstructured":"Liu T, Li Q, Lin Z, et al. A single-arm phase II study of nab-paclitaxel plus gemcitabine and cisplatin for locally advanced or metastatic biliary tract cancer. Cancer Res Treat. 2024;56(2):602\u201315.","journal-title":"Cancer Res Treat"},{"issue":"6","key":"1215_CR29","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1001\/jamaoncol.2019.0270","volume":"5","author":"RT Shroff","year":"2019","unstructured":"Shroff RT, Javle MM, Xiao L, et al. Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial. JAMA Oncol. 2019;5(6):824\u201330.","journal-title":"JAMA Oncol"},{"issue":"4","key":"1215_CR30","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/jso.24147","volume":"113","author":"M Suenaga","year":"2016","unstructured":"Suenaga M, Yamada S, Fujii T, et al. S-1 plus nab-paclitaxel is a promising regimen for pancreatic cancer in a preclinical model. J Surg Oncol. 2016;113(4):413\u20139.","journal-title":"J Surg Oncol"},{"issue":"54","key":"1215_CR31","doi-asserted-by":"crossref","first-page":"92401","DOI":"10.18632\/oncotarget.21359","volume":"8","author":"Y Shi","year":"2017","unstructured":"Shi Y, Zhang S, Han Q, et al. Nab-paclitaxel plus S-1 in advanced pancreatic adenocarcinoma (NPSPAC): a single arm, single center, phase II trial. Oncotarget. 2017;8(54):92401\u201310.","journal-title":"Oncotarget"},{"issue":"4","key":"1215_CR32","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s00280-018-3650-4","volume":"82","author":"W Zhang","year":"2018","unstructured":"Zhang W, Du C, Sun Y, et al. Nab-paclitaxel plus S-1 as first-line followed by S-1 maintenance for advanced pancreatic adenocarcinoma: a single-arm phase II trial. Cancer Chemother Pharmacol. 2018;82(4):655\u201360.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"1215_CR33","doi-asserted-by":"crossref","first-page":"37","DOI":"10.21037\/hbsn-21-172","volume":"12","author":"W Zhang","year":"2023","unstructured":"Zhang W, Sun Y, Jiang Z, Qu W, Gong C, Zhou A. Nab-paclitaxel plus tegafur gimeracil oteracil potassium capsule (S-1) as first-line treatment for advanced biliary tract adenocarcinoma: a phase 2 clinical trial. Hepatobiliary Surg Nutr. 2023;12(1):37\u201344.","journal-title":"Hepatobiliary Surg Nutr"},{"key":"1215_CR34","doi-asserted-by":"publisher","unstructured":"Moehler M, Shitara K, Garrido M, Salman P, Shen L, Wyrwicz L et al. LBA6_PR - nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer\/gastroesophageal junction cancer (GC\/GEJC)\/esophageal adenocarcinoma (EAC): first results of the CheckMate 649 study. Ann Oncol. 2020;31(suppl_4):S1142-S1215. https:\/\/doi.org\/10.1016\/annonc\/annonc325.","DOI":"10.1016\/annonc\/annonc325"},{"issue":"5","key":"1215_CR35","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.annonc.2021.02.006","volume":"32","author":"DJ McGrail","year":"2021","unstructured":"McGrail DJ, Pili\u00e9 PG, Rashid NU, et al. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann Oncol. 2021;32(5):661\u201372.","journal-title":"Ann Oncol"},{"issue":"7","key":"1215_CR36","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1001\/jamaoncol.2019.0626","volume":"5","author":"A Addeo","year":"2019","unstructured":"Addeo A, Banna GL, Weiss GJ. Tumor mutation burden-from hopes to doubts. JAMA Oncol. 2019;5(7):934\u20135.","journal-title":"JAMA Oncol"},{"issue":"10","key":"1215_CR37","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.7150\/thno.56539","volume":"11","author":"J Lin","year":"2021","unstructured":"Lin J, Cao Y, Yang X, et al. Mutational spectrum and precision oncology for biliary tract carcinoma. Theranostics. 2021;11(10):4585\u201398.","journal-title":"Theranostics"},{"key":"1215_CR38","doi-asserted-by":"publisher","unstructured":"Mie T, Sasaki T, Okamoto T et al. Current status of targeted therapy for biliary tract cancer in the era of precision medicine. Cancers (Basel). 2024;16(5). https:\/\/doi.org\/10.3390\/cancers16050879","DOI":"10.3390\/cancers16050879"},{"key":"1215_CR39","doi-asserted-by":"publisher","unstructured":"Valle JW, Qin S, Antonuzzo L et al. 68O Impact of mutation status on efficacy outcomes in TOPAZ-1: a phase 3 study of durvalumab or placebo plus gemcitabine and cisplatin in advanced biliary tract cancer. 2022 ESMO ASIA. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.104","DOI":"10.1016\/j.annonc.2022.10.104"},{"issue":"24","key":"1215_CR40","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1002\/cncr.30254","volume":"122","author":"M Javle","year":"2016","unstructured":"Javle M, Bekaii-Saab T, Jain A, et al. Biliary cancer: utility of next-generation sequencing for clinical management. Cancer. 2016;122(24):3838\u201347.","journal-title":"Cancer"},{"issue":"9","key":"1215_CR41","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1158\/2159-8290.CD-17-0245","volume":"7","author":"JW Valle","year":"2017","unstructured":"Valle JW, Lamarca A, Goyal L, Barriuso J, Zhu AX. New horizons for precision medicine in biliary tract cancers. Cancer Discov. 2017;7(9):943\u201362.","journal-title":"Cancer Discov"},{"issue":"4","key":"1215_CR42","doi-asserted-by":"crossref","first-page":"652","DOI":"10.21037\/jgo.2018.08.18","volume":"10","author":"BA Weinberg","year":"2019","unstructured":"Weinberg BA, Xiu J, Lindberg MR, et al. Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets. J Gastrointest Oncol. 2019;10(4):652\u201362.","journal-title":"J Gastrointest Oncol"},{"issue":"3","key":"1215_CR43","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.trecan.2020.01.005","volume":"6","author":"JJ Adashek","year":"2020","unstructured":"Adashek JJ, Subbiah IM, Matos I, et al. Hyperprogression and immunotherapy: fact, fiction, or alternative fact. Trends Cancer. 2020;6(3):181\u201391.","journal-title":"Trends Cancer"},{"issue":"5","key":"1215_CR44","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.cllc.2021.03.006","volume":"22","author":"L Cabez\u00f3n-Guti\u00e9rrez","year":"2021","unstructured":"Cabez\u00f3n-Guti\u00e9rrez L, Custodio-Cabello S, Palka-Kotlowska M, Alonso-Viteri S, Khosravi-Shahi P. Biomarkers of immune checkpoint inhibitors in non-small cell lung cancer: beyond PD-L1. Clin Lung Cancer. 2021;22(5):381\u20139.","journal-title":"Clin Lung Cancer"},{"issue":"3","key":"1215_CR45","doi-asserted-by":"crossref","first-page":"100688","DOI":"10.1016\/j.currproblcancer.2020.100688","volume":"45","author":"H Zhang","year":"2021","unstructured":"Zhang H, Fang X, Li D, et al. Hyperprogressive disease in patients receiving immune checkpoint inhibitors. Curr Probl Cancer. 2021;45(3):100688.","journal-title":"Curr Probl Cancer"},{"issue":"1","key":"1215_CR46","first-page":"147","volume":"5","author":"P Ding","year":"2022","unstructured":"Ding P, Wen L, Tong F, Zhang R, Huang Y, Dong X. Mechanism underlying the immune checkpoint inhibitor-induced hyper-progressive state of cancer. Cancer Drug Resist. 2022;5(1):147\u201364.","journal-title":"Cancer Drug Resist"},{"key":"1215_CR47","doi-asserted-by":"crossref","first-page":"678409","DOI":"10.3389\/fphar.2021.678409","volume":"12","author":"P Shen","year":"2021","unstructured":"Shen P, Han L, Ba X, Qin K, Tu S. Hyperprogressive disease in cancers treated with immune checkpoint inhibitors. Front Pharmacol. 2021;12:678409.","journal-title":"Front Pharmacol"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01215-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-025-01215-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01215-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T22:25:51Z","timestamp":1743719151000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-025-01215-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1215"],"URL":"https:\/\/doi.org\/10.1007\/s12029-025-01215-x","relation":{},"ISSN":["1941-6628","1941-6636"],"issn-type":[{"value":"1941-6628","type":"print"},{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,1]]},"assertion":[{"value":"25 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the independent ethics committee of the Chinese People\u2019s Liberation Army General Hospital (No. S2019-201\u201301).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Informed consent was obtained from all individual participants included in the study. Patients were informed of the purpose, procedures, risks, and benefits of the study, and their consent was documented in writing.This statement is to ensure transparency and integrity in our research and publication processes.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"90"}}